Insulin-Like Growth Factor Binding Protein-2 Level Is Increased in Blood of Lung Cancer Patients and Associated with Poor Survival

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Guo, Chengcheng ^a,b   Lu, Haibo ^a,c   Gao, Wen ^a   Wang, Li ^a   Lu, Kaihua ^a   Wu, Shuhong ^a   Pataer, Apar ^a   Huang, Maosheng ^a   El Zein, Randa ^a   Lin, Tongyu ^b   Roth, Jack A ^a   Mehran, Reza ^a   Hofstetter, Wayne ^a   Swisher, Stephen G ^a   Wu, Xifeng ^a   Fang, Bingliang ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SURVIVAL TIME; TUMOR VOLUME; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

CALCIUM; DNA PRIMERS; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MCF-7 CELLS; MICROSCOPY, FLUORESCENCE; MYOBLASTS; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN;

EID: 84884257696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074973     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300. doi:10.3322/caac.20073. PubMed: 20610543.
2. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, et al. (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409. doi:10.1056/NEJMoa1102873. PubMed: 21714641.
3. Goulart BH, Bensink ME, Mummy DG, Ramsey SD, (2012) Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 10: 267-275. PubMed: 22308519.
4. Salgia R, (2011) Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 117: 3889-3899. doi:10.1002/cncr.25935. PubMed: 21858799.
5. Holdenrieder S, Nagel D, Stieber P, (2010) Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomarkers 6: 179-190. PubMed: 20660963.
6. Wheatcroft SB, Kearney MT, (2009) IGF-dependent and IGF-independent actions of IGF-binding protein-1 and-2: implications for metabolic homeostasis. Trends Endocrinol Metab 20: 153-162. doi:10.1016/j.tem.2009.01.002. PubMed: 19349193.
7. Baxter RC, (2000) Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 278: E967-E976. PubMed: 10826997.
8. Mehta HH, Gao Q, Galet C, Paharkova V, Wan J, et al. (2011) IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res 71: 5154-5163. doi:10.1158/1538-7445.AM2011-5154. PubMed: 21697285.
9. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, et al. (2002) Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 62: 3530-3537. PubMed: 12068000.
10. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, et al. (2007) Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A 104: 11736-11741. doi:10.1073/pnas.0703145104. PubMed: 17606927.
11. Russo VC, Schütt BS, Andaloro E, Ymer SI, Hoeflich A, et al. (2005) Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146: 4445-4455. doi:10.1210/en.2005-0467. PubMed: 15994346.
12. Png KJ, Halberg N, Yoshida M, Tavazoie SF, (2012) A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481: 190-194.
13. Hsieh D, Hsieh A, Stea B, Ellsworth R, (2010) IGFBP2 promotes glioma tumor stem cell expansion and survival. Biochem Biophys Res Commun 397: 367-372. doi:10.1016/j.bbrc.2010.05.145. PubMed: 20515648.
14. Azar WJ, Azar SH, Higgins S, Hu JF, Hoffman AR, et al. (2011) IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology 152: 3332-3342. doi:10.1210/en.2011-1121. PubMed: 21750048.
15. Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, et al. (2011) DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neurooncol 13: 280-289. PubMed: 21339190.
16. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjørnsen T, et al. (2005) Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 58: 361-366. doi:10.1136/jcp.2004.020834. PubMed: 15790698.
17. Probst-Hensch NM, Steiner JH, Schraml P, Varga Z, Zürrer-Härdi U, et al. (2010) IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res 16: 1025-1032. doi:10.1158/1078-0432.CCR-09-0957. PubMed: 20103684.
18. Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, et al. (2006) High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer 16: 1529-1535. doi:10.1111/j.1525-1438.2006.00623.x. PubMed: 16884361.
19. Ambrosini-Spaltro A, Farnedi A, Montironi R, Foschini MP, (2011) IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma. Appl Immunohistochem Mol Morphol 19: 318-328. doi:10.1097/PAI.0b013e3128052936. PubMed: 21304397.
20. Mishra L, Bass B, Ooi BS, Sidawy A, Korman L, (1998) Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm Igf Res 8: 473-479. doi:10.1016/S1096-6374(98)80300-6. PubMed: 10985759.
21. Zhang L, Huang W, Chen J, Zhou X, Lu Z, Zhou H, (2007) Expression of IGFBP2 in gastric carcinoma and relationship with clinicopathologic parameters and cell proliferation. Dig Dis Sci 52: 248-253. doi:10.1007/s10620-006-9358-z. PubMed: 17171534.
22. He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, et al. (2012) Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLOS ONE 7: e31087. doi:10.1371/journal.pone.0031087. PubMed: 22348039.
23. Kühnl A, Kaiser M, Neumann M, Fransecky L, Heesch S, et al. (2011) High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res 35: 1585-1590. doi:10.1016/j.leukres.2011.08.006. PubMed: 21899885.
24. Becher OJ, Peterson KM, Khatua S, Santi MR, MacDonald TJ, (2008) IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. J Child Neurol 23: 1205-1213. doi:10.1177/0883073808321766. PubMed: 18952587.
25. Lin Y, Jiang T, Zhou K, Xu L, Chen B, et al. (2009) Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neurooncol 11: 468-476. PubMed: 19164435.
26. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG, (1993) Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76: 1031-1035. doi:10.1210/jc.76.4.1031. PubMed: 7682560.
27. Ho PJ, Baxter RC, (1997) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 46: 333-342. PubMed: 91560449135695.
28. Baron-Hay S, Boyle F, Ferrier A, Scott C, (2004) Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 10: 1796-1806. doi:10.1158/1078-0432.CCR-0672-2. PubMed: 15014034.
29. Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, et al. (2010) Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab 95: 1717-1725. doi:10.1210/jc.2009-2668. PubMed: 20157191.
30. Ladd JJ, Busald T, Johnson MM, Zhang Q, Pitteri SJ, et al. (2012) Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women. Cancer. Prev Res 5: 655-664. doi:10.1158/1940-6207.CAPR-11-0412.
31. Inman BA, Harel F, Audet JF, Meyer F, Douville P, et al. (2005) Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol 47: 695-702. doi:10.1016/j.eururo.2004.12.015. PubMed: 15826765.
32. Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, et al. (2011) Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or-independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 104: 1587-1593. doi:10.1038/bjc.2011.127. PubMed: 21487405.
33. Zhang Y, Ying X, Han S, Wang J, Zhou X, et al. (2013) Autoantibodies against insulin-like growth factorbinding protein-2 as a serological biomarker in the diagnosis of lung cancer. Int J Oncol 42: 93-100. PubMed: 23165420.
34. Matuschek C, Rudoy M, Peiper M, Gerber PA, Hoff NP, et al. (2011) Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur J Med Res 16: 451-456. doi:10.1186/2047-783X-16-10-451. PubMed: 22024424.
35. Stieber P, Hasholzner U, Bodenmüller H, Nagel D, Sunder-Plassmann L, et al. (1993) CYFRA 21-1. A new marker in lung cancer. Cancer 72: 707-713. doi:10.1002/1097-0142(19930801)72:3. PubMed: 7687515.
36. Patz EF Jr., Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE, (2007) Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25: 5578-5583. doi:10.1200/JCO.2007.13.5392. PubMed: 18065730.
37. Schneider J, (2006) Tumor markers in detection of lung cancer. Adv Clin Chem 42: 1-41. doi:10.1016/S0065-2423(06)42001-1. PubMed: 17131623.
38. Mattsson A, Svensson D, Schuett B, Osterziel KJ, Ranke MB, (2008) Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults. Growth Horm Igf Res 18: 506-516. doi:10.1016/j.ghir.2008.04.005. PubMed: 18550406.
39. Clemmons DR, Snyder DK, Busby WH Jr., (1991) Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 73: 727-733. doi:10.1210/jcem-73-4-727. PubMed: 1716260.
40. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, et al. (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 104: 5563-5568. doi:10.1073/pnas.0609139104. PubMed: 17372210.
41. Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, et al. (2009) IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A 106: 16675-16679. doi:10.1073/pnas.0900807106. PubMed: 19805356.
42. Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, et al. (2012) Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kappaB network. Proc Natl Acad Sci U S A 109: 3475-3480. doi:10.1073/pnas.1120375109. PubMed: 22345562.